Market Analysis and Price Projections for Erythromycin Ophthalmic Ointment (NDC: 24208-0910)
Overview of Erythromycin Ophthalmic Ointment
Erythromycin ophthalmic ointment, with the NDC code 24208-0910, is a macrolide antibiotic used to treat various bacterial infections of the eye. It is manufactured by Bausch & Lomb Incorporated and is available in 3.5g and 1g tubes[1].
Market Dynamics
Global Erythromycin Market
The global erythromycin market is driven by several factors, including the rising prevalence of infectious diseases such as respiratory tract infections and skin and soft tissue infections. According to a study by the Bill & Melinda Gates Foundation, lower respiratory tract infections resulted in 2.74 million deaths and 103.0 million disability-adjusted life-years (DALYs) globally in 2015, which is expected to increase the demand for antibiotics like erythromycin[4].
Regional Market
The North American market is expected to hold a dominant position in the global erythromycin market due to increasing regulatory approvals and the prevalence of skin and soft tissue infections. For instance, Rising Pharmaceuticals, Inc. launched an FDA-approved generic version of Benzamycin Gel in 2016, which contributes to the market growth[4].
Price Trends
Current Pricing
The average pharmacy cost for Erythromycin 0.5% Eye Ointment with the NDC code 24208-0910-19 is approximately $3.83 per gram as of December 2024. Similar pricing is observed for other NDC codes associated with the same product[5].
Price Projections
The overall pharmaceutical market is expected to see a price increase, with Vizient, Inc. projecting a 3.8% drug price inflation in 2024, driven partly by specialty pharmaceuticals. However, this projection is more relevant to high-cost, complex, or chronic condition treatments rather than generic antibiotics like erythromycin ointment[2].
For generic drugs like erythromycin ointment, the price trend is generally stable or slightly increasing due to manufacturing costs and market competition. The introduction of biosimilars and generic versions can sometimes lead to price stability or minor reductions, but this is less likely to impact the pricing of erythromycin ointment significantly[2].
Competitive Landscape
The erythromycin market is competitive, with several key players including Ani Pharmaceuticals, Akorn, Inc., Aceto Corporation, Genesis Pharmaceuticals, Teligent, Inc., Abbvie, Inc., Abbott Laboratories, Pfizer, Inc., Sanofi-Aventis, and Allergan, Plc. These companies are focused on developing, manufacturing, and marketing multisource and branded pharmaceuticals, which helps in maintaining market competition and pricing stability[4].
Regulatory Approvals and Impact
Recent regulatory approvals, such as the FDA approval for Erythromycin Tablets USP by Amneal Pharmaceuticals in 2018 and the approval for Erythromycin Topical Gel USP by Teligent, Inc. in 2017, indicate a favorable regulatory environment. These approvals help in increasing access to affordable medications and can influence the pricing dynamics by ensuring a steady supply of generic alternatives[4].
Challenges and Limitations
Despite the positive market trends, there are challenges such as allergic reactions to erythromycin and the increasing availability of alternative antibiotics like azithromycin. Additionally, concerns about the use of erythromycin during pregnancy, as it is linked to higher risks of epilepsy and cerebral palsy in newborn babies, can also impact market growth[4].
Key Takeaways
- Market Growth: Driven by the rising prevalence of infectious diseases and regulatory approvals.
- Price Stability: Expected due to generic competition and stable manufacturing costs.
- Regional Dominance: North America is expected to hold a dominant position.
- Competitive Landscape: Multiple key players ensure market competition and pricing stability.
- Regulatory Environment: Favorable regulatory approvals support market growth.
- Challenges: Allergic reactions, alternative antibiotics, and pregnancy-related concerns.
FAQs
-
What is the primary use of Erythromycin Ophthalmic Ointment?
- Erythromycin ophthalmic ointment is used to treat bacterial infections of the eye.
-
Which company manufactures Erythromycin Ophthalmic Ointment with NDC code 24208-0910?
- Bausch & Lomb Incorporated.
-
What are the key drivers of the global erythromycin market?
- Rising prevalence of infectious diseases and increasing regulatory approvals.
-
How is the price of Erythromycin Ophthalmic Ointment expected to change in the near future?
- The price is expected to remain relatively stable due to generic competition and stable manufacturing costs.
-
What are some challenges facing the erythromycin market?
- Allergic reactions, increasing availability of alternative antibiotics, and pregnancy-related concerns.
Sources
- DailyMed - ERYTHROMYCIN ointment[1]
- Vizient Projects 3.8% Drug Price Increase Driven by Specialty Pharmaceuticals[2]
- ASPE - Antimicrobial Drugs Market Returns Analysis[3]
- Coherent Market Insights - Erythromycin Market[4]
- Drug Patent Watch - Pharmaceutical drug prices and trends for ERYTHROMYCIN[5]
